ORBIMED ADVISORS LLC
Q3 2023 13F-HR Holdings
Net value change ($000)
-811,345
(-14.7%)
New positions
16
Sold out positions
14
Turnover %
16.5%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q2 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| MRK | 108,612 | NEW |
| APLM | 63,590 | 1675.2% |
| RayzeBio, Inc. | 58,229 | NEW |
| Mirati Therapeutics, Inc. | 52,326 | 158.5% |
| ABBV | 49,190 | NEW |
| ICLR | 32,554 | NEW |
| APGE | 30,414 | NEW |
| NMRA | 21,165 | NEW |
| CI | 21,048 | 46.6% |
| NPCE | 21,024 | 116.7% |
Top Reduces (Value $000, Stocks/ETFs)
| Theseus Pharmaceuticals, Inc. | -113,140 | -70.4% |
| BMY | -95,158 | -100.0% |
| VectivBio Holding AG | -87,662 | -100.0% |
| UNH | -81,983 | -69.9% |
| BAX | -69,231 | -45.0% |
| ISRG | -66,321 | -31.3% |
| ELVN | -60,739 | -33.1% |
| ACELYRIN, Inc. | -57,152 | -51.3% |
| EW | -48,580 | -100.0% |
| MDGL | -37,289 | -50.2% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
45,975
(1.0% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|